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In this issue of Cell Reports, Van den Bossche et al. (2016) reveal that, once the M1 macrophage
forms, the accompanying metabolic alterations in the mitochondria are irreversible, preventing
differentiation into the more homeostatic M2 macrophage.Macrophages are a frontline cell in host
defense and inflammation, participating
in the handling of infectious agents
but also restoring homeostasis once the
trauma has passed. As such, they are
highly plastic and respond to different
environmental cues by adopting different
effector states, as required by the prevail-
ing conditions. The best understood sce-
nario consists of macrophages occurring
in two quite distinct ‘‘flavors.’’ When
the stimulus is lipopolysaccharide (LPS)
from gram-negative bacteria in combina-
tion with interferon g (IFNg; as might
prevail during bacterial infection), they
adopt an inflammatory phenotype (usually
termed M1 macrophages, or as recently
proposed, M[LPS + IFNg]) (Murray et al.,
2014). However, when activated by cyto-
kines such as IL-4 or IL-13, they adopt
a more reparative phenotype (M2 macro-
phages or M[IL-4]). These macrophages
are also more prominent in tumors or
during helminth infections and in allergy,
where they contribute to pathology.
Therefore, a lot of attention has focused
on the molecular basis for these
differing responses, one aim being to
reprogram macrophages from one state
to another for therapeutic gain. Attention
has recently focused on metabolic differ-
ences between these states. M1 macro-
phages have impaired oxidative phos-
phorylation and rely on glycolysis for
ATP production. This impairment is partly
due to the Krebs cycle being broken inM1
macrophages, with the intermediates cit-
rate and succinate taking on the roles of
membrane biogenesis and HIF1a activa-
tion, respectively (Tannahill et al., 2013;
Jha et al., 2015; Galva´n-Pen˜a and O’Neill,
2014). On the other hand, M2 macro-This is an open access arphages have an intact Krebs cycle and
use oxidative phosphorylation as the
main means of ATP generation. In this
issue of Cell Reports, Van den Bossche
et al. (2016) provide new insights into
this aspect of macrophage regulation
by demonstrating that, once the macro-
phage has committed to being M1, it
cannot be reprogrammed to an M2
by IL-4. However, the opposite is not
apparent—the M2 can be converted to
an M1 by the addition of LPS. The mech-
anism involves an impairment in the mito-
chondrial electron transport chain in the
M1 macrophage that is caused by nitric
oxide (NO) in the mouse and cannot be
overcome. This study confirms the impor-
tance of metabolic reprogramming for
macrophage function and might have
relevance for therapeutic manipulation of
macrophages in disease.
The study began with attempts to repo-
larize either human or mouse macro-
phages from M1 to M2 using IL-4. With
the exception of arginase, a host of M2
markers were not inducible by IL-4.
Intriguingly, IL-4 signaling (as indicated
by STAT6 phosphorylation) was intact in
this protocol. In contrast, LPS + IFNg
treatment was able to induce M1 markers
in M2 macrophages, indicating that the
M2 phenotype was more plastic. Impor-
tantly these resultswere confirmed in vivo.
Metabolic analysis confirmed enhanced
glycolysis and impaired oxidative phos-
phorylation in the M1 macrophage, with
oxidative phosphorylation being more
evident in the M2 macrophage. Further
analysis revealed that M1 macrophages
had a dysfunctional electron transport
chain, being unable to respire under con-
ditions where substrates were provided toCel
ticle under the CC BY-NC-ND license (http://crcomplexes I, II or III. IL-4 was unable to
restore respiration in theM1macrophage.
Also of note was the observation that oli-
gomycin (which inhibits the ATP synthase)
or 2-deoxyglucose (which inhibits glycol-
ysis) both suppressed the induction of
M2 macrophages by IL-4. This indicates
that glucose feeds the Krebs cycle for
respiration in the M2 macrophage and
that inhibition of this will prevent polariza-
tion to M2.
Van den Bossche et al. (2016) then
turned to a possible mechanism of
impaired respiration in the M1 macro-
phage. Previous studies in other cell types
had pointed to NO as being able to block
respiration by nitrosylating components
in the electron transport chain (Clementi
et al., 1998). Inducible NO synthase
(iNOS) inhibition prior to LPS + IFNgmark-
edly improved respiration and also made
the M1 macrophage amenable to reprog-
ramming to an M2 phenotype by IL-4. It
did not block induction of the M1 pheno-
type but instead made the M1 macro-
phage more responsive to IL-4 in terms
of induction of M2 markers. Therefore,
these results indicate that NO is the
damaging agent for the electron transport
chain, with this damage preventing IL-4
from repolarizing the macrophage to M2
(Figure 1).
Van den Bossche et al. (2016) further
emphasize metabolic reprogramming as
being a critical event in macrophage po-
larization. NO appears to play a critical
role here, and inhibitors of iNOS might
have potential as agents for promoting
M2 polarization. An important point
to note is that the mechanism may
be different in humans. The authors
demonstrate a similar lack of plasticity inl Reports 17, October 11, 2016 ª 2016 625
eativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Metabolic Polarization of Macrophages
Treatment of macrophages with LPS + IFNg leads to NO generation, which
impedes the electron transport chain and respiration, driving the pro-inflam-
matory phenotype of these cells. IL-4 promotes oxidative phosphorylation,
which promotes an anti-inflammatory phenotype. The inflammatory M1
macrophage cannot be repolarized to an M2 macrophage by IL-4 unless NO
generation is blocked. However, the anti-inflammatory M2 macrophage can
be repolarized to an M1 macrophage by LPS + IFNg.human M1 macrophages but
the mechanism is unlikely to
involve NO. They speculate
that the metabolite taconite
might be involved (Lampro-
poulou et al., 2016). The
actual mechanism of irrevers-
ibility in the M1 phenotype re-
quires further analysis, and as
proposed by the authors, may
entail epigenetic changes in
key genes that might be
responsible for the stability of
the M1 phenotype. The work
also highlights the importance
of alterations in the electron
transport chain in M1 macro-
phages as indicated in two
other recent studies (Garaude
et al., 2016; Mills et al.,
2016). Succinate dehydroge-nase (complex II) has been shown to
be a key control point, driving reverse
electron transport in complex I in the
LPS-activated macrophage to promote
reactive oxygen species generation, a
hallmark of the M1 macrophage (Mills
et al., 2016).
The study also provides new informa-
tion on howM2macrophages arise during
the resolution of inflammation. The lack of
plasticity in the formed M1 macrophage
means that the M2 macrophage must
come fromprecursormacrophages rather
than the conversion of the M1 macro-
phage into M2. However, it might be
possible to provide inhibitors that will pro-
mote this process in the context of an
inflammatory environment. For example,626 Cell Reports 17, October 11, 2016inhibition of SDH or of the enzyme PKM2
(which governs the switch to glycolysis)
will promote anM2phenotype in response
to LPS (Palsson-McDermott et al., 2015).
Further studies will help to unravel
the complex metabolic events occurring
in this most important of cell types and
possibly point to therapeutic approaches
for manipulating them in inflammatory
and allergic diseases and cancer.REFERENCES
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